Febrile Neutropenia in a Blinded Trial: SAE Reporting and Unblinding
An 18-site Phase III double-blind trial is evaluating an investigational oral JAK inhibitor in adults with moderate-to-severe ulcerative colitis. A 42-year-old participant randomized 5 weeks ago calls the research nurse reporting fever of 39.1°C, sore throat, and painful oral ulcers that began 3 days ago. The participant is admitted to the hospital for intravenous antibiotics and isolation. Laboratory results: absolute neutrophil count 0.3 × 10^9/L, platelets 88 × 10^9/L, hemoglobin 9.2 g/dL. The investigator's note says 'febrile neutropenia, possibly related to study drug.' The protocol lists neutropenia as an expected adverse event but does not list febrile neutropenia or agranulocytosis. The site is blinded, and the pharmacy has not unblinded. The sponsor's 24-hour safety line closes in 4 hours. The coordinator is also preparing for a scheduled monitoring visit.
1. Is this a serious adverse event and a suspected unexpected serious adverse reaction? What must be reported, to whom, and by when?
Read the worked answer
Yes, this is a serious adverse event because it caused hospitalization; the very low ANC with fever also raises a life-threatening concern if it worsens. Expectedness is assessed against the investigator brochure or protocol reference safety information. The protocol lists neutropenia, but febrile neutropenia and agranulocytosis are not listed; a more severe or specific syndrome is generally unexpected even when a milder term appears. Causality is documented as 'possibly related,' meaning there is a reasonable possibility that the drug caused the event. That combination makes it a suspected unexpected serious adverse reaction from the site's perspective, subject to sponsor assessment.
The coordinator must report to the sponsor's safety desk within 24 hours of first awareness, not wait for the monitoring visit. The initial report should include subject identifier, event term, onset and admission dates, relevant labs, concomitant medications, investigator causality, seriousness criteria, and blinded treatment status. Do not delay for the full hospital discharge summary; send follow-up when available. Also notify the PI and report to the IRB per local policy. The sponsor handles regulatory SUSAR reporting, but the site must provide complete follow-up and respond to queries.
2. Should the site break the blind? Justify your answer and describe who decides and how it is documented.
Read the worked answer
Do not break the blind reflexively. Emergency unblinding is justified only when knowledge of treatment assignment changes the participant's immediate medical management, not merely because the event is serious or because the coordinator wants to know. Febrile neutropenia is usually managed with broad-spectrum antibiotics, cultures, and supportive care regardless of whether the participant received active drug or placebo; holding study drug may be protocol-directed and does not always require knowing assignment.
The decision belongs to the PI in consultation with the sponsor medical monitor, using the protocol's emergency unblinding procedure. If the PI determines that management depends on assignment, use the emergency system, document the reason, date, time, and person who authorized it, and notify the sponsor immediately. Keep the unblinding information restricted to those who need it for care. If the blind is not broken, report the event as blinded and do not speculate in the source or eCRF about assignment. Either way, document the rationale for the unblinding decision so the monitor and auditor can see that it was a clinical judgment, not curiosity.
3. What follow-up and documentation should the coordinator complete, and what should be ready for the monitor?
Read the worked answer
Open an SAE file and an AE log entry with the onset date, hospitalization dates, severity grade, causality, expectedness, and outcome. Obtain and file the admission history, physical, cultures, complete blood count with differential, concomitant medications including antibiotics and growth factors, and discharge summary. Track the event until resolution or stabilization and send follow-up reports within the sponsor's timeline.
Source documentation should show who was notified and when, including the sponsor safety line, PI, IRB, and pharmacy. Record the blinded status and any unblinding decision. Do not backdate or alter earlier notes; use dated addenda. For the monitor, prepare the SAE form, source worksheets, lab reports, medication administration record, delegation log showing the reporter was trained, and the protocol section on safety reporting. The coordinator should also check whether the event triggers expedited reporting to the IRB and whether the consent form's risk section needs revision. The monitoring visit should not be used as the reporting mechanism; it is an opportunity to verify that the 24-hour report was complete and timely.